Bhargavi Pulluri is an Oncology physician. OpenAlex indexes 11 publications with 214 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
900 Caton Ave
Baltimore, MD 21229
Telephone
602-748-9758Registry record last updated 16 Aug 2018.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Caris MPI, Inc.Program year20251 payment
- Mirati Therapeutics, Inc.Program year20231 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
47%Aromatase Inhibitor24.5%Anastrozole83%Letrozole17%Part D≥85 patientsKinase inhibitor9.6%Jakafi30%Imbruvica20%Kisqali15%Ibrance13%Tagrisso11%Gleevec10%Part D<11 patients+ 5 more classes in this area
Nervous system
15.8%Opioid Agonist6.5%Oxycodone Hcl46%Tramadol Hcl31%Morphine Sulfate Er23%Part D<11 patientsGabapentinoids4.4%Gabapentin100%Part D≥16 patients+ 3 more classes in this area
Blood & clotting
14.9%Factor Xa inhibitor13%Xarelto54%Eliquis46%Part D≥17 patientsVitamin K antagonist0.9%Jantoven100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis
DOAJ (DOAJ: Directory of Open Access Journals)
2022 - Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Journal of Clinical Oncology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”